Holen Sie sich die Stockscreener-App
0.85
5.57%
-0.0501
Handel nachbörslich:
.85
Schlusskurs vom Vortag:
$0.9001
Offen:
$0.9
24-Stunden-Volumen:
56,851
Relative Volume:
0.45
Marktkapitalisierung:
$5.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.44M
KGV:
-0.053
EPS:
-16.0242
Netto-Cashflow:
$-28.30M
1W Leistung:
-20.56%
1M Leistung:
-6.76%
6M Leistung:
-56.85%
1J Leistung:
-87.04%
1-Tages-Spanne:
$0.8411
$0.90
1-Wochen-Bereich:
$0.8113
$1.34
52-Wochen-Spanne:
$0.6911
$10.79
Nucana Plc Adr Stock (NCNA) Company Profile
Vergleichen Sie NCNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
0.85 | 5.45M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-03 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-22 | Eingeleitet | Truist | Buy |
| 2020-07-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-23 | Eingeleitet | Citigroup | Buy |
| 2017-10-23 | Eingeleitet | Jefferies | Buy |
| 2017-10-23 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Nucana Plc Adr Aktie (NCNA) Neueste Nachrichten
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana plc Announces Reverse ADS Split - TipRanks
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Will NuCana Continue to Surge Higher? - Nasdaq
NuCana (NCNA) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Nucana Plc Adr-Aktie (NCNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):